NCT01636778View on ClinicalTrials.gov

Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

SB-497115-GR

TPO receptor agonist to increase platelet count

Trial Locations (16)

467-8602

GSK Investigational Site, Aichi

918-8503

GSK Investigational Site, Fukui

803-8505

GSK Investigational Site, Fukuoka

830-0011

GSK Investigational Site, Fukuoka

370-0829

GSK Investigational Site, Gunma

663-8501

GSK Investigational Site, Hyōgo

317-0077

GSK Investigational Site, Ibaraki

760-0017

GSK Investigational Site, Kagawa

760-8557

GSK Investigational Site, Kagawa

899-5112

GSK Investigational Site, Kagoshima

213-8587

GSK Investigational Site, Kanagawa

856-8562

GSK Investigational Site, Nagasaki

540-0006

GSK Investigational Site, Osaka

879-5593

GSK Investigational Site, Ōita

105-8470

GSK Investigational Site, Tokyo

646-8558

GSK Investigational Site, Wakayama

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY